1
|
Brisotto G, Muraro E, Montico M, Corso C, Evangelista C, Casarotto M, Caffau C, Vettori R, Cozzi MR, Zanussi S, Turetta M, Ronchese F, Steffan A. IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers. Clin Chim Acta 2021; 523:476-482. [PMID: 34755649 PMCID: PMC8555109 DOI: 10.1016/j.cca.2021.10.035] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Revised: 10/27/2021] [Accepted: 10/27/2021] [Indexed: 11/19/2022]
Abstract
BACKGROUND AND AIMS Monitoring the immune response against SARS-CoV-2 is pivotal in the evaluation of long-term vaccine efficacy. Immunoglobulin G (IgG) antibodies represent an advisable tool to reach this goal, especially for the still poorly defined antibody trend induced by the new class of mRNA vaccines against SARS-CoV-2. MATERIALS AND METHODS Anti-Spike RBD IgG antibodies were monitored in a cohort of healthcare workers at CRO Aviano, National Cancer Institute, through MAGLUMI® chemiluminescence assay, at 1 and 4 months after full-schedule of BNT162b2 or mRNA-1273 vaccination. RESULTS At 1 month after vaccination, 99.9% of 767 healthcare workers showed a reactive antibody response, which was inversely correlated with age, and positively associated with a previous history of COVID-19, and mRNA-1273 vaccination. Serological response was maintained in 99.6% of the 516 subjects monitored also at follow-up. An antibody decay from 559.8 AU/mL (IQR 359.7-845.7) to 92.7 AU/mL (IQR 65.1-148.6; p < 0.001) was observed, independently from age and sex. CONCLUSION Our data supported the ability of SARS-CoV-2 mRNA vaccines to induce at least a 4 months-lasting IgG response, even outside the rules of clinical trials. The antibody decay observed at follow-up suggested to deepen the immune response characterization to identify subjects with low anti-SARS-CoV-2 immunity possibly requiring a vaccination boost.
Collapse
Affiliation(s)
- Giulia Brisotto
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| | - Elena Muraro
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy.
| | - Marcella Montico
- Clinical Trial Office, Scientific Direction, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| | - Chiara Corso
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| | - Chiara Evangelista
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| | - Mariateresa Casarotto
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| | - Cristina Caffau
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| | - Roberto Vettori
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| | - Maria Rita Cozzi
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| | - Stefania Zanussi
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| | - Matteo Turetta
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| | - Federico Ronchese
- Clinical Unit of Occupational Medicine, Department of Medical Sciences, University of Trieste, 34100 Trieste, Italy
| | - Agostino Steffan
- Immunopathology and Cancer Biomarkers Units, Department of Translational Research, CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, PN, Italy
| |
Collapse
|
2
|
Simonelli C, Zanussi S, Pratesi C, Rupolo M, Talamini R, Caffau C, Teresa Bortolin M, Tedeschi R, Basaglia G, Mazzucato M, Manuele R, Vaccher E, Spina M, Tirelli U, Michieli M, De Paoli P. Immune Recovery after Autologous Stem Cell Transplantation Is Not Different for HIV‐Infected versus HIV‐Uninfected Patients with Relapsed or Refractory Lymphoma. Clin Infect Dis 2010; 50:1672-9. [DOI: 10.1086/652866] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
3
|
Patussi V, Barbina P, Barbone F, Valent F, Bubbi R, Caffau C, Driussi C, Munafò G, Rosolen V, Venturini C, Zanin T, Zuliani C. [Comparison of the incidence rate of occupational injuries among permanent, temporary and immigrant workers in Friuli-Venezia Giulia]. Epidemiol Prev 2008; 32:35-38. [PMID: 18488952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
OBJECTIVES to evaluate the difference in the frequency of occupational injuries between permanent and temporary workers, and between Italian and immigrant workers. DESIGN we compared the incidence rate of occupational injury between permanent and temporary workers and between Italian and immigrant workers. SETTING 160 factories and 4 employment agencies operating in Friuli-Venezia Giulia, Italy. PARTICIPANTS all permanent workers of the above-named factories and temporary workers of the above-named employment agencies. MAIN OUTCOME MEASURES incidence rate ratio of occupational injury in relation to type of workers (permanent and temporary) and their nationality (Italian and immigrant). RESULTS there were 1,499 occupational injuries among 18,210 permanent workers and 392 among 1,345 temporary workers. The incidence rate ratio of occupational injury was significantly higher in temporary workers than in permanent workers (IR 2.46; 95% CI 2.02-2.99). Nationality appears to be an important risk factor especially among permanent workers (IR 1.63; 95% CI 1.34-1.98). Temporary work--regardless nationality--seems to be a major risk for occupational injury.
Collapse
Affiliation(s)
- Valentino Patussi
- Dipartimento di prevenzione, Struttura complessa prevenzione e sicurezza negli ambienti di lavoro, Azienda per i servizi sanitari no 1, Trieste.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Pratesi C, Simonelli C, Zanussi S, Talamini R, Bortolin MT, Tedeschi R, Marus A, Caffau C, Michieli M, Tirelli U, De Paoli P. Recent thymic emigrants in lymphoma patients with and without human immunodeficiency virus infection candidates for autologous peripheral stem cell transplantation. Clin Exp Immunol 2007; 151:101-9. [PMID: 17931391 DOI: 10.1111/j.1365-2249.2007.03516.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Signal joint T cell receptor excision circles (sjTRECs) have been reported as a clinical marker to measure the potential for recovery of the immune system after immunosuppressive treatments. The aim of this study was to investigate the thymic regenerative potential in 55 human immunodeficiency virus (HIV)-1 infected (HIV(+)) and non-infected (HIV(-)) lymphoma patients, candidates for autologous stem cell transplantation (ASCT). Moreover, the possible associations between sjTRECs and other immunological and clinical parameters were examined. SjTRECs levels in peripheral blood mononuclear cells (PBMCs) were quantified by real-time polymerase chain reaction and T lymphocyte subsets were analysed by flow cytometry. Our data showed that sjTRECs were reduced in lymphoma patients compared to healthy controls, although a weak significant association between low sjTRECs levels and increasing age was maintained [odds ratio (OR) = 4.00; 95% confidence interval (CI) 1.09-17.17]. We found that different chemotherapeutic treatments seem to induce similar effects on the thymic reservoir, independently from their intensity (type and number of cycles of previous chemotherapy). Results from multivariate models including adjustment for patients' sex, type of lymphoma and type of chemotherapy showed that thymic output was independent from HIV infection (OR, 0.95; 95% CI 0.20-4.48). SjTRECs levels correlated with naive T cell subsets in overall lymphoma patients and after stratification by HIV infection (r > 0.37). HIV replication should be maximally suppressed to properly evaluate thymic output by sjTREC markers. Our results suggested that de novo T cell generation is maintained partially in pretreated recurrent lymphoma patients, candidates for ASCT, and could contribute to restore the immune function after transplantation.
Collapse
Affiliation(s)
- C Pratesi
- Microbiology, Immunology and Virology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Pin E, Tedeschi R, Zanussi S, Marus A, Bortolin M, Pratesi C, Caffau C, Simonelli C, De Paoli P. LINFOMA SOLIDO HHV8 ASSOCIATO DOPO TRAPIANTO AUTOLOGO: CASE REPORT. Microbiol Med 2007. [DOI: 10.4081/mm.2007.2820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
6
|
Tedeschi R, Berton M, Pratesi C, Pin E, Marus A, Bortolin M, Caffau C, Simonelli C, Zanussi S, De Paoli P. MONITORAGGIO VIROLOGICO ED IMMUNOLOGICO IN PAZIENTI RICEVENTI TRAPIANTO AUTOLOGO DI CELLULE STAMINALI (ASCT). Microbiol Med 2006. [DOI: 10.4081/mm.2006.3391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
7
|
Costanzo C, Bortolin M, Pratesi C, Bidoli E, Zanussi S, Caffau C, D’Andrea M, Averna P, Varaschin P, Crepaldi C, Simonelli C, Tedeschi R, De Paoli P. ASPETTI VIROLOGICI ED IMMUNOLOGICI IN PAZIENTI HIV+ E HIV- SOTTOPOSTI A TRAPIANTO AUTOLOGO DI CELLULE STAMINALI. Microbiol Med 2004. [DOI: 10.4081/mm.2004.3762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
8
|
Zanussi S, Vaccher E, Caffau C, Pratesi C, Crepaldi C, Bortolin MT, Tedeschi R, Politi D, Barzan L, Tirelli U, De Paoli P. Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 2003; 52:28-32. [PMID: 12536237 PMCID: PMC11034241 DOI: 10.1007/s00262-002-0333-z] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2002] [Accepted: 08/22/2002] [Indexed: 10/25/2022]
Abstract
An efficent antitumor and antiviral cellular immune response requires optimal interferon-gamma (IFN-gamma) secretion and perforin expression in CD8(+) T cells. The aim of this study was to define whether CD4(+) and CD8(+) T cells from patients with undifferentiated carcinoma of nasopharyngeal type (UCNT), a tumor regularly associated with the Epstein-Barr virus (EBV), have abnormal phenotype profiles, cytokine production, perforin and CD3-zeta expressions. Our data showed that CD4 and CD8 subset distribution was not grossly altered in the peripheral blood of UCNT patients, while tumor biopsies contained an increased proportion of CD8(+) T cells. The analysis of the CD4(+) subset showed a defect in interleukin-2 (IL-2) production and a moderate increase of IL-10 production, a situation consistent with a Th1/Th2 imbalance. We have also demonstrated that CD8(+) lymphocytes from UCNT patients had a marked impairment of IFN-gamma secretion and perforin expression. This impairment was not related to the presence of detectable EBV DNA in the plasma. In UCNT patients, the blockade of the perforin pathway and of IFN-gamma production may constitute important mechanisms for immune escape by the tumor and for impaired control of EBV replication.
Collapse
Affiliation(s)
- Stefania Zanussi
- Department of Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, IRCCS, Via Pedemontana 12, 33081 Aviano, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Caggiari L, Zanussi S, Crepaldi C, Bortolin MT, Caffau C, D'Andrea M, De Paoli P. Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2-treated human immunodeficiency virus-positive subjects. Cytometry 2001; 46:233-7. [PMID: 11514956 DOI: 10.1002/cyto.1132] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Interleukin-2 (IL-2) has been used successfully to increase CD4 cell counts in patients who are human immunodeficiency virus (HIV) positive. The mechanisms involved in this phenomenon are unknown. We hypothesized that a differential proliferation rate of CD4+ compared with CD8+ lymphocytes could be related to the increase of CD4 counts and of CD4/CD8 ratios that occur in HIV+ patients during IL-2 treatment. METHODS We enrolled in our study 14 HIV+ patients treated with IL-2 or with highly active antiretroviral therapy (HAART) during a 96-week observation period. Using flow cytometry, we measured longitudinally the expression of the Ki67 antigen in peripheral blood CD4+ and CD8+ lymphocyte subsets. RESULTS Compared with HAART alone, IL-2 produced a rapid increase of Ki67+ proliferating CD4 cells and a concomitant increase of the CD4/CD8 ratios, whereas the corresponding CD8 proliferation increased slightly. On the contrary, HAART alone was effective in suppressing equally both CD4 and CD8 proliferation. CONCLUSIONS Our results suggest a selective activity of IL-2 on CD4 T-cell proliferation; on the contrary, CD8-specific proliferation is affected minimally during treatment. This information may offer the potential to plan correctly immune activating regimens.
Collapse
Affiliation(s)
- L Caggiari
- Division of Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy
| | | | | | | | | | | | | |
Collapse
|
10
|
Caggiari L, Zanussi S, D'Andrea M, Bortolin MT, Crepaldi C, Caffau C, Paoli PD. Effects of interleukin-2 therapy on the proliferation and differentiation of CD4/CD25 positive and CD4/CD25 negative cells in HIV+ patients. Eur Cytokine Netw 2001; 12:430-6. [PMID: 11566623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Interleukin-2 has been widely used in HIV-1+ subjects as an immunoactivating agent. In this study, we investigated cytokine production, Ki67 antigen expression and the modulation of the surface phenotype of the CD4/CD25+ subset as compared to the reciprocal CD4/CD25- subset in IL-2-treated HIV+ patients. Our findings suggest that CD4 T cells are heterogeneous in responding to IL-2, because CD4/CD25+ cells sharply increased their "memory" phenotype, their Ki67 antigen expression and were the main in vivo targets for IL-2-dependent proliferation during therapy, while the percentages of IFN-gamma+ (terminally differentiated) cells remained unchanged at the end of therapy. Conversely, the CD4+/CD25- subpopulation showed an expansion of differentiated cells and a slight increase in the proliferation rate. The use of anti-retroviral therapy alone (HAART) reduced the proliferation and increased the differentiation of both CD4 subsets. Our data suggest that IL-2 has a moderate capacity to activate resting T cells in vivo and is probably unable to boost HIV-1 from latency to the replicative state.
Collapse
Affiliation(s)
- L Caggiari
- Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | |
Collapse
|
11
|
De Paoli P, Vaccher E, Tedeschi R, Caffau C, Zanussi S, Bortolin MT, Crepaldi C, Spina M, Tirelli U. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy. Cancer Immunol Immunother 2001; 50:157-62. [PMID: 11419183 PMCID: PMC11036840 DOI: 10.1007/s002620100185] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The anti-CD20 monoclonal antibody Rituximab is a novel antitumor agent used in association with chemotherapy (CT) for the treatment of high-grade/intermediate non-Hodgkin's lymphomas (NHL) in HIV-negative populations. This therapeutic combination is currently also being explored in HIV-positive patients with NHL (HIV-NHL). The objective of our study was to determine CD4 and CD8T cell counts, HIV plasma viremia and proviral load in patients with CD20-positive HIV-NHL treated with Rituximab plus CT and highly active antiretroviral therapy (HAART). We studied eight patients with HIV-NHL treated by anti-CD20 and CT before, after three, and after six cycles of therapy; CD4, CD8 and CD19 lymphocyte subsets were measured by monoclonal antibodies and flow cytometry. HIV plasma viremia was determined by the b-DNA assay, and proviral load by a quantitative competitive PCR. CD4T cell counts remained stable after three cycles of therapy, while a significant reduction of this subset was present at the end of therapy. HIV plasma viremia was significantly reduced after the third cycle, but returned to pretreatment levels at the end of therapy; we also observed individual fluctuations of proviral load during therapy, this marker being increased in two out of three patients at the end of therapy. These observations suggest that Rituximab plus CT accelerated the rate of CD4 depletion and of HIV replication in the peripheral blood of HIV-NHL patients and that HAART may be able to delay these effects.
Collapse
MESH Headings
- Adult
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD19/biosynthesis
- Antigens, CD20/immunology
- Antineoplastic Agents/therapeutic use
- CD4-Positive T-Lymphocytes/metabolism
- CD8-Positive T-Lymphocytes/metabolism
- Female
- Flow Cytometry
- HIV/metabolism
- HIV Seropositivity/immunology
- Humans
- Leukocytes, Mononuclear/virology
- Lymphocyte Subsets/metabolism
- Lymphocyte Subsets/virology
- Lymphoma, Non-Hodgkin/immunology
- Lymphoma, Non-Hodgkin/therapy
- Lymphoma, Non-Hodgkin/virology
- Male
- Middle Aged
- RNA, Messenger/metabolism
- Rituximab
- Time Factors
Collapse
Affiliation(s)
- P. De Paoli
- />Departments of Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, IRCCS, via Pedemontana, 33081 Aviano, Italy e-mail: Tel.: +39-04-34659404 Fax: +39-04-34659402, , , , IT
| | - E. Vaccher
- />Medical Oncology A, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy, , , , IT
| | - R. Tedeschi
- />Departments of Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, IRCCS, via Pedemontana, 33081 Aviano, Italy e-mail: Tel.: +39-04-34659404 Fax: +39-04-34659402, , , , IT
| | - C. Caffau
- />Departments of Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, IRCCS, via Pedemontana, 33081 Aviano, Italy e-mail: Tel.: +39-04-34659404 Fax: +39-04-34659402, , , , IT
| | - S. Zanussi
- />Departments of Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, IRCCS, via Pedemontana, 33081 Aviano, Italy e-mail: Tel.: +39-04-34659404 Fax: +39-04-34659402, , , , IT
| | - M. T. Bortolin
- />Departments of Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, IRCCS, via Pedemontana, 33081 Aviano, Italy e-mail: Tel.: +39-04-34659404 Fax: +39-04-34659402, , , , IT
| | - C. Crepaldi
- />Departments of Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, IRCCS, via Pedemontana, 33081 Aviano, Italy e-mail: Tel.: +39-04-34659404 Fax: +39-04-34659402, , , , IT
| | - M. Spina
- />Medical Oncology A, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy, , , , IT
| | - U. Tirelli
- />Medical Oncology A, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy, , , , IT
| |
Collapse
|
12
|
Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997; 26:871-9. [PMID: 9126802 DOI: 10.1016/s0168-8278(97)80255-3] [Citation(s) in RCA: 143] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND/AIMS Several studies have demonstrated that diabetic patients with cirrhosis require insulin treatment because of insulin resistance. As chronic alcoholic liver damage is partly due to the lipoperoxidation of hepatic cell membranes, anti-oxidizing agents may be useful in treating or preventing damage due to free radicals. The aim of this study was to ascertain whether long-term treatment with silymarin is effective in reducing lipoperoxidation and insulin resistance in diabetic patients with cirrhosis. METHODS A 12-month open, controlled study was conducted in two well-matched groups of insulin-treated diabetics with alcoholic cirrhosis. One group (n=30) received 600 mg silymarin per day plus standard therapy, while the control group (n=30) received standard therapy alone. The efficacy parameters, measured regularly during the study, included fasting blood glucose levels, mean daily blood glucose levels, daily glucosuria levels, glycosylated hemoglobin (HbA1c) and malondialdehyde levels. RESULTS There was a significant decrease (p<0.01) in fasting blood glucose levels, mean daily blood glucose levels, daily glucosuria and HbA1c levels already after 4 months of treatment in the silymarin group. In addition, there was a significant decrease (p<0.01) in fasting insulin levels and mean exogenous insulin requirements in the treated group, while the untreated group showed a significant increase (p<0.05) in fasting insulin levels and a stabilized insulin need. These findings are consistent with the significant decrease (p<0.01) in basal and glucagon-stimulated C-peptide levels in the treated group and the significant increase in both parameters in the control group. Another interesting finding was the significant decrease (p<0.01) in malondialdehyde/levels observed in the treated group. CONCLUSIONS These results show that treatment with silymarin may reduce the lipoperoxidation of cell membranes and insulin resistance, significantly decreasing endogenous insulin overproduction and the need for exogenous insulin administration.
Collapse
Affiliation(s)
- M Velussi
- Anti-Diabetes Centre, Monfalcone Hospital, Gorizia, Italy
| | | | | | | | | | | |
Collapse
|
13
|
Zanelli GD, Quaia M, Robieux I, Bujor L, Santarosa M, Favaro D, Spada A, Caffau C, Gobitti C, Trovò MG. Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 1997; 33:486-92. [PMID: 9155536 DOI: 10.1016/s0959-8049(97)89026-0] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Paclitaxel is efficacious against many human cancers. Because it blocks cells at the radiosensitive G2-M interface, paclitaxel has been investigated as a radiosensitiser. The results have been equivocal and somewhat contradictory. It is impossible to obtain proper pharmacokinetic calculations, aimed at obtaining maximum cytotoxicity and/or radiosensitisation, without knowing (i) how long the drug must be in contact with the cells, (ii) how long the effect lasts after the drug is removed from the cellular environment, (iii) whether the drug acts as a radiosensitiser even when, like cis-platinum, it is added after the radiation and (iv) what the minimum quantity of drug in the cellular environment is required for both chemotoxicity and radiosensitisation. The present work addresses the above questions. Two radioresistant cell lines of human origin were used, A375 melanoma and S549 lung carcinoma, in a clonogenic assay where only colonies with 50 or more cells were counted. For the irradiation, 6 MV X-rays were used. Any G2-M block was quantified by cell cycle kinetics analysis. From the results, a simulation of pharmacokinetics was conducted to calculate the schedule of administration of paclitaxel most likely to achieve and maintain significant chemotoxocity and radiosensitisation. The minimum concentration of paclitaxel for measurable cytotoxicity was 3 nM for both cell lines, but the drug was more toxic to the A549 cells. The minimum concentration for measurable radiosensitisation was 3 nM for A375 and approximately 0.1 nM for A549, but whereas above 3 nM the radiosensitivity increased in A375, it decreased above 1 nM for A549. A minimum of 18 h incubation with the drug was necessary for measurable effects and the radiosensitising effects were lost soon after its removal. There was no radiosensitisation if paclitaxel was added after the radiation, and, at the minimum effective concentrations, it caused only a minor and transient G2-M block. The pharmacokinetic calculations predict that 15 mg/m2 paclitaxel given as a 1 h infusion 5 days/week for 3 weeks during the radiotherapy should achieve both cytotoxicity and radiosensitisation. The mechanism of radiosensitisation by paclitaxel at the concentrations suggested by our results does not appear to be via a G2-M block and is probably concentration dependent. The results imply that low-dose, daily infusions of paclitaxel for as long as possible during a course of radiotherapy are more likely to result in radiosensitisation and prolonged cytotoxicity than high-dose infusions given once a week.
Collapse
Affiliation(s)
- G D Zanelli
- Laboratorio di Immunoterapia, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Zanussi S, Simonelli C, D'Andrea M, Caffau C, Clerici M, Tirelli U, DePaoli P. CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin Exp Immunol 1996; 105:220-4. [PMID: 8706325 PMCID: PMC2200507 DOI: 10.1046/j.1365-2249.1996.d01-746.x] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
In most HIV-1-infected patients, clinical and immunological progression develops within a few years. Few infected people, termed long-term non-progressors (LTNP), remain healthy and immunologically stable for a long time. The factors governing the maintenance of this condition are not well known, but it is conceivable that CD8+ lymphocytes, cells that play a central role in controlling in vitro HIV replication, may have a part in vivo in this process. The aim of this study was to characterize the phenotypic profile and the cytokine production of CD8+ cells in a group of LTNP patients who had stable CD4+ cell counts (> 500/mm3) for at least 7 years. Their CD8+ absolute numbers were similar to a control group composed of HIV-1+ patients who have a progressive decline of their CD4+ cell counts. However, our multiparameter immunofluorescence studies show that a clinical and immunologically stable condition is associated with the presence of a CD28+, CD95 strongly positive CD8+ population, while disease progression is marked by the CD28-CD95+CD8+ subset. Purified CD8+ cells from LTNP retain their ability to produce IL-2, interferon-gamma (IFN-gamma) and, to a lesser degree, to produce IL-10 and IL-4. In contrast, CD8+ cells from progressors are unable to secrete IL-2 and IL-10. Although CD8+ cytokine profile does not fit with the proposed T helper (Th)1/Th2 switch in progressive HIV infection, LTNP CD8+ T cells maintain their capacity to produce IL-2 and IL-10 (Th0-like), a pattern very similar to that observed in normal HIV healthy controls. We suggest that CD8+ cells expressing CD28, CD95 and having a Th0-like profile may be considered to be associated with long-term survival.
Collapse
Affiliation(s)
- S Zanussi
- Department of Microbiology-Immunology-Virology, C.R.O. Aviano, Italy
| | | | | | | | | | | | | |
Collapse
|
15
|
De Paoli P, Caffau C, D'Andrea M, Tavio M, Tirelli U, Santini G. Serum levels of intercellular adhesion molecule 1 in patients with HIV-related Kaposi's sarcoma. J Acquir Immune Defic Syndr (1988) 1994; 7:695-9. [PMID: 7911526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Infection with the human immunodeficiency virus type 1 (HIV-1) in man is associated with an increase in the incidence of Kaposi's sarcoma (KS). The biological and clinical characteristics of these patients differ from those of subjects with other HIV-associated diseases. Here we report that levels of serum-soluble intercellular adhesion molecule 1 (sICAM 1) are increased in HIV-1-positive patients with KS, but not in patients belonging to other CDC classification groups. KS patients with elevated levels of serum sICAM 1 had a significant lowering of CD4 cell counts during the follow-up period compared with those KS subjects whose sICAM 1 levels were only moderately higher. We suggest that increased sICAM 1 levels may have a pathogenetic role in the development of HIV-associated immunodeficiency in KS patients and may also be considered an important prognostic factor.
Collapse
Affiliation(s)
- P De Paoli
- Microbiology-Immunology-Virology Division, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | |
Collapse
|
16
|
De Paoli P, Caffau C, D'Andrea M, Ceolin P, Simonelli C, Tirelli U, Santini G. The expansion of CD8 lymphocytes using T cell receptor variable gene products during HIV infection. Clin Exp Immunol 1993; 94:486-9. [PMID: 7902788 PMCID: PMC1534445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Fresh peripheral blood was obtained from HIV-infected subjects and from age-matched healthy controls. Single-, two- and three-colour flow cytometry was performed using FITC-labelled MoAbs directed against the following TCR V beta subfamilies: V2, V3, V5a, V5b, V5c, V6, V8, V12, V13.3, V17, V19, alone or in combination with PE-labelled CD4, CD8, HLA-DR, CD28, CD38 and with Peridinin-chlorophyll A protein (PerCP)-conjugated CD8. The percentages of each V beta subfamily did not differ in HIV+ patients compared with healthy controls. However, we were able to find in four patients (one CDC group II, one group III and two group IV) an expansion of a TCR V beta subfamily (V3 in two, V5a and V19 in one patient). These cells were mainly CD8+. Three-colour flow cytometry allowed us to define that the expanded V beta+, CD8+ T lymphocytes were characterized by the low/intermediate expression of activation markers (HLA-DR, CD28, CD38). In some HIV+ patients there is an expansion of T cells expressing a TCR V beta subfamily; the nature of this expansion may be related to factors that are still unknown, such as the genetic background of each individual and the antigenic specificity of T cells. These populations may be relevant in the host response to the virus and in disease progression.
Collapse
Affiliation(s)
- P De Paoli
- Microbiology-Immunology-Virology Division, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | | | | | |
Collapse
|
17
|
Velussi M, Cernigoi A, Viezzoli L, Dapas F, Caffau C, Zilli M. Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Current Therapeutic Research 1993. [DOI: 10.1016/s0011-393x(05)80660-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Velussi M, Cernigoi A, Viezzoli L, Caffau C. Treatment of arterial hypertension in non-insulin-dependent diabetic patients: Comparison of doxazosin and enalapril. Curr Ther Res Clin Exp 1993. [DOI: 10.1016/s0011-393x(05)80791-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
19
|
Velussi M, Cernigoi AM, Viezzoli L, Caffau C. [Median-term (4 months) treatment with glibenclamide + metformin substituting for glibenclamide + fenformin lowers the lacticemia levels in type-2 diabetics (NIDDM)]. Clin Ter 1992; 141:483-92. [PMID: 1493670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
60 NIDDM patients, mean age (68 +/- 3 years), BMI (25 +/- 5.1 kg/m2), fasting blood glucose (FG) (170 +/- 10 mg/dl), mean daily blood glucose (MDBG) (180 +/- 10 mg/dl), daily glycosuria (GLU) (15.6 +/- 9 g/24 hours), HbA1c (7.9 +/- 0.6%), basal (1.2 +/- 0.2 ng/ml) and stimulated (3.89 +/- 1.3 mg/ml) C peptide (CP) treated by ASS (7.5 +/- 75 mg), after a strict 4 months follow-up period, were assigned to G + M treatment (7.5 +/- 1.500 mg) during a 4 months period. During G+M treatment FG (171 +/- 13 at t0 to 165 +/- 11 mg/dl: p < 0.01 at t4) varied significantly. MDBG (180 +/- 10 at t0 to 175 +/- 12 mg/dl at t4:p < 0.05), GLU (16 +/- 9 at t0 to 11 + 6 g/24 hours at t4; p < 0.01), HbA1c (8.1 +/- 0.4 at t0 to 7.6 +/- 0.3% at t4; p < 0.01). Basal CP remained unchanged in G+M period and varied significantly during ASS period (1.3 +/- 0.3 ng/ml at t4; p < 0.01) and stimulated CP (unchanged during ASS) was reduced during G+M (4.19 +/- 0.4 to 4.04; p < 0.05). Highly significant variations were observed for LAC (28.4 +/- 2.1 at t0 to 14.9 +/- 0.6 mg/dl: p < 0.01 during G+M treatment). G+M therapy was found to be more effective and safer than ASS therapy in regard to glucose metabolism and lactate production in a selected group of NIDDM patients.
Collapse
Affiliation(s)
- M Velussi
- Centro Antidiabetico, Presidio Ospedaliero di Monfalcone
| | | | | | | |
Collapse
|